Letermovir and Valcyte drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Letermovir (letermovir) and Valcyte (valganciclovir hydrochloride). Common drug interactions include cytomegalovirus viraemia among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Letermovir and Valcyte. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Letermovir?

Letermovir has active ingredients of letermovir. eHealthMe is studying from 949 Letermovir users. Check the latest studies of Letermovir.

What is Valcyte?

Valcyte has active ingredients of valganciclovir hydrochloride. It is often used in cmv - immunocompromised host. eHealthMe is studying from 6,409 Valcyte users. Check the latest studies of Valcyte.



On Jul, 16, 2026

20 people who take Letermovir and Valcyte together, and have interactions are studied.

Letermovir and Valcyte drug interactions.

What are the common drug interactions of Letermovir and Valcyte, by gender? *:

female:

  1. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  2. Dehydration (dryness resulting from the removal of water)
  3. Headache (pain in head)
  4. Hypophagia (reduced food intake)
  5. Lactic acidosis (low ph in body tissues)
  6. Nausea (feeling of having an urge to vomit)
  7. Nephropathy toxic (damage to kidney due to toxins)
  8. Oral herpes (viral infection of mouth)
  9. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  10. Poor peripheral circulation

male:

  1. Pyrexia (fever)
  2. Immunosuppressant drug level increased
  3. Dyspnoea (difficult or laboured respiration)
  4. Eye pruritus (eye itching)
  5. Eye swelling
  6. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  7. Hepatotoxicity (chemical-driven liver damage)
  8. Laryngeal oedema (swelling of larynx)
  9. Pneumonia aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree)
  10. Throat irritation

What are the common drug interactions of Letermovir and Valcyte, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  2. Dehydration (dryness resulting from the removal of water)
  3. Headache (pain in head)
  4. Hypophagia (reduced food intake)
  5. Lactic acidosis (low ph in body tissues)
  6. Nausea (feeling of having an urge to vomit)
  7. Oral herpes (viral infection of mouth)
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Poor peripheral circulation
  10. Staphylococcal infection (an infection with staphylococcus bacteria)

30-39:

n/a

40-49:

  1. Immunosuppressant drug level increased
  2. Drug ineffective
  3. Pyrexia (fever)
  4. Hepatotoxicity (chemical-driven liver damage)
  5. Alanine aminotransferase increased
  6. Aspartate aminotransferase increased
  7. Cytomegalovirus test positive
  8. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  9. Roseolovirus test positive

50-59:

  1. Anaphylactic reaction (serious allergic reaction)
  2. Blood pressure increased
  3. Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
  4. Cough
  5. Cytomegalovirus viraemia (cytomegalo virus in blood stream)
  6. Dysplasia (enlargement of an organ or tissue)
  7. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  9. Immunosuppression
  10. Infection susceptibility increased

60+:

  1. Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

  1. Cytomegalovirus Infection: 10 people, 50.00%
  2. Human Herpesvirus 6 Infection: 8 people, 40.00%
  3. Pulmonary Mass: 5 people, 25.00%
  4. High Blood Pressure: 5 people, 25.00%
  5. Nausea (feeling of having an urge to vomit): 4 people, 20.00%
  6. Pain: 4 people, 20.00%
  7. Nausea And Vomiting: 4 people, 20.00%
  8. Cytomegalovirus Viraemia (cytomegalo virus in blood stream): 3 people, 15.00%
  9. Fungaemia (fungi circulate in the blood): 3 people, 15.00%
  10. Type 2 Diabetes: 3 people, 15.00%

* Approximation only. Some reports may have incomplete information.

Do you take Letermovir and Valcyte?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Letermovir and Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Letermovir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Letermovir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valcyte and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on letermovir and valganciclovir hydrochloride (the active ingredients of Letermovir and Valcyte, respectively), and Letermovir and Valcyte (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: